Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics
- PMID: 15373940
- PMCID: PMC1884607
- DOI: 10.1111/j.1365-2125.2004.02159.x
Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics
Figures
References
-
- Figgitt DP, Plosker GL. Saquinavir soft-gel capsule. An updated review of its use in the management of HIV infection. Drugs. 2000;60:481–516. - PubMed
-
- Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P4503A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci. 1998;87:1322–30. - PubMed
-
- Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol. 1998;54:53–8. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
